The FDA draft guidance for communications with payers and formulary committees was widely anticipated, but offers little in the way of surprises. The agency has drawn very tight lines about what may be discussed for approved products, disallowing even a communication about the long-term benefits of a drug approved only for acute treatment of the underlying disease.